Clinical Trial Update: Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11% [Phase 3]

View source ↗

Summary

Extension-phase completion update for a Phase 3 study evaluating the efficacy and safety of vildagliptin in patients with type 2 diabetes and HbA1c 9-11%.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Vildagliptin (vildagliptin)

Snippet

Sponsor: Novartis | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED